Infex Therapeutics to present new RESP-X Phase IIa data in late-breaking session at ERS Congress 2026
Presentation will provide additional analysis from the Phase IIa study of…
Infex Therapeutics written submission to the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB)
Below is the text that Infex Therapeutics submitted to the Presidential…
Infex Therapeutics announces positive Phase IIa results for RESP-X in non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa
Study met its primary objective demonstrating excellent safety and…
Infex Therapeutics secures £4.3 million funding to advance anti-infective pipeline targeting drug-resistant infections
Alderley Park, Cheshire, U.K. – 12 May 2026, Infex Therapeutics, a leading…
World AMR Awareness Week 2025
This World AMR Awareness Week, we're proud to be celebrating our collaboration…
UK Government investment is vital to combat AMR
Professor Janet Hemingway, iiCON Founding Director Dr Pete Jackson,…
Infex agrees collaboration with Asian clinical trials network, ADVANCE-ID
Memorandum of Understanding signed to investigate hospital-acquired…
Infex signs exclusive license agreement with Venus Remedies Ltd to advance MET-X through clinical development and commercialisation in India
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Infex and Justus-Liebig-University Giessen awarded £1 million grant from PACE
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
First NCFB patient dosed in Phase IIa study of RESP-X
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…